Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.34) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34), MarketWatch Earnings reports. Capricor Therapeutics had a negative net margin of 660.66% and a negative return on equity of 264.61%. The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.07 million.
Shares of CAPR traded down $0.05 during midday trading on Thursday, reaching $1.07. The stock had a trading volume of 288,354 shares, compared to its average volume of 174,151. Capricor Therapeutics has a 1-year low of $0.88 and a 1-year high of $8.85. The company’s fifty day simple moving average is $1.29 and its two-hundred day simple moving average is $1.90. The company has a market cap of $4.97 million, a price-to-earnings ratio of -0.37 and a beta of 2.16.
Several equities analysts have commented on the stock. Maxim Group raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, February 3rd. Zacks Investment Research raised shares of Capricor Therapeutics from a “hold” rating to a “strong-buy” rating and set a $2.00 price target for the company in a research report on Thursday, January 23rd. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, January 21st. Finally, ValuEngine raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd.
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Story: What is a Market Correction?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.